GlassScriptPhysician profile
Dave K Jain
NPI 1265540777
$4,728.15
in general payments reported to CMS, 2019-2025
30 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $1,107 · 2021: $889 · 2022: $636 · 2023: $596 · 2024: $270 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008 · Education: $56.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.83 |
| Education | $56.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,139.98 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $690.90 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $654.93 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $451.44 | 2019-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $348.57 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $237.22 | 2020-2022 | |
| Lilly USA, LLC | $174.66 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $131.92 | 2019-2022 | |
| Pfizer INC. | $129.53 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $121.70 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $115.83 | 2019 | |
| Sunovion Pharmaceuticals INC. | $106.99 | 2021-2022 | |
| Grifols USA, LLC | $91.73 | 2020-2024 | Prolastin-C Liquid |
| Otsuka America Pharmaceutical, INC. | $63.45 | 2020-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $48.75 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.55 | 2020-2022 | |
| Abbvie INC. | $18.77 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.88 | 2023 | |
| Alkermes, INC. | $15.49 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.15 | 2020 | |
| Xeris Pharmaceuticals, INC. | $14.61 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $14.24 | 2025 | Dexcom G6 Transmitter |
| Acorda Therapeutics, INC | $14.20 | 2019 | |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Gilead Sciences, INC. | $13.48 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.40 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $12.82 | 2021 | |
| Abbott Laboratories | $12.22 | 2022 | |
| Eisai INC. | $11.67 | 2020 | |
| Sumitomo Pharma America, INC. | $11.17 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dave Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.